← All trials
NCT04446637
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Sep 30, 2021
- Completion date
- Sep 30, 2021
- First posted
- Jun 25, 2020
- Last posted
- Jun 25, 2020
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NeuTec PharmaLead sponsor
- Cukurova UniversityOverall official - principal investigator
- Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.